Business Context and Reporting Period
This Form 6-K filing covers the month of February 2019 for Anchiano Therapeutics Ltd. (referred to as Chemomab Therapeutics Ltd. in metadata). The registrant is a foreign private issuer based in Jerusalem, Israel, reporting the closing of its initial public offering (IPO).
Key Financial Metrics
- Gross Proceeds: $30.5 million from the IPO.
- Shares Issued: 2,652,174 American Depositary Shares (ADSs), each representing five ordinary shares.
- Offering Price: $11.50 per ADS.
- Capital Increase: 13,260,870 ordinary shares added to outstanding share capital to facilitate the transfer to the depositary.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics.
Material Changes
The primary material change is the transition to a publicly traded company via the closing of the IPO on February 14, 2019. This event significantly increased the company's cash position through gross proceeds of $30.5 million and expanded its outstanding share capital.
Guidance, Outlook, and Risks
The filing focuses on the execution of the IPO and the associated legal agreements (Underwriting Agreement with Oppenheimer & Co. Inc. and the Deposit Agreement). It does not contain specific forward-looking guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the standard incorporation of the press release and underwriting documents.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds are stated.
- Review the attached Underwriting Agreement (Exhibit 1.1) for lock-up periods and indemnification terms.
- Confirm the exact number of ordinary shares underlying the ADSs and the total post-IPO share count.
- Examine the press release (Exhibit 99.1) for any additional details on the use of proceeds not included in this summary.